← Eichor
Study identifier: NCT05617326 Synced from ClinicalTrials.gov · July 31, 2026
● Recruiting

Screening for Abdominal Aortic Aneurysms in the General Practice by Ultraportable Ultrasound

Condition: Abdominal Aortic Aneurysm  ·  Sponsor: Fondation Ophtalmologique Adolphe de Rothschild

PhaseNA
Planned participants400
Who can joinMale, 50 Years to 75 Years
Healthy volunteersYes

About this study

Abdominal aortic aneurysm (AAA) is a localized dilatation of a segment of the aorta artery in its abdominal portion. It affects 1.7% of men aged 65 years and older. In the high-risk population (male smokers aged 65-75 years), its prevalence is estimated to be between 2.8 and 9%. Mortality of ruptured AAAs is high (80% of deaths before hospitalization or perioperatively), whereas mortality of scheduled procedures for unruptured AAAs is less than 5%. AAA screening has been shown to significantly reduce the specific mortality rate in the medium and long term. The French National Authority for Health (HAS) recommends targeted screening for AAA by ultrasound at the radiologist. The target population is male smokers or former smokers aged 65 to 75 years, as well as all persons aged 50 to 75 years with a family history of AAA. Despite recommendations, the rate of access to targeted screening appears low. Ultrasound screening for AAA is a rapid, noninvasive, and reproducible test. It relies primarily on the measurement of the maximum diameter of the abdominal aorta in cross-section. It has been demonstrated that the learning of the ultrasound screening procedure for AAA is very fast and that the performance of non-radiologists trained in this procedure alone is similar to that of radiologists. In addition, new ultra-portable ultrasound devices, inexpensive and with validated performances have appeared on the market in the last few years, making it possible to equip general practitio…

This description comes directly from the study's public registry record.

Talk to the study team

Amélie YAVCHITZ, MD  ·  148036454  ·  ayavchitz@for.paris

Always discuss trial participation with your own doctor first.

Locations (5)

Cabinet IPSO BrotteauxLyon, FranceRecruiting
Cabinet IPSO Saint MartinParis, FranceRecruiting
Cabinet IPSO NationParis, FranceRecruiting
Cabinet IPSO ItalieParis, FranceRecruiting
Cabinet IPSO OurcqParis, FranceRecruiting

Follow this study

Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.

We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05617326